S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Biden's Plan to Confiscate Your Cash? (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
US Dollar Replaced By "Biden Bucks"? (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Biden's Plan to Confiscate Your Cash? (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
US Dollar Replaced By "Biden Bucks"? (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Biden's Plan to Confiscate Your Cash? (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
US Dollar Replaced By "Biden Bucks"? (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Biden's Plan to Confiscate Your Cash? (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
US Dollar Replaced By "Biden Bucks"? (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
NASDAQ:CDXS

Codexis - CDXS Stock Forecast, Price & News

$8.84
+0.50 (+6.00%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$8.31
$8.95
50-Day Range
$6.67
$12.86
52-Week Range
$6.15
$42.01
Volume
758,561 shs
Average Volume
1.95 million shs
Market Capitalization
$578.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.33

Codexis MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
141.3% Upside
$21.33 Price Target
Short Interest
Bearish
8.37% of Float Sold Short
Dividend Strength
N/A
Sustainability
-3.67
Upright™ Environmental Score
News Sentiment
0.57mentions of Codexis in the last 14 days
Based on 13 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.48) to ($0.71) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Medical Sector

926th out of 1,135 stocks

Industrial Organic Chemicals Industry

16th out of 21 stocks

CDXS stock logo

About Codexis (NASDAQ:CDXS) Stock

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Codexis Price Performance

NASDAQ:CDXS traded up $0.50 during trading hours on Friday, reaching $8.84. 758,561 shares of the company were exchanged, compared to its average volume of 1,953,754. Codexis has a 52-week low of $6.15 and a 52-week high of $42.01. The stock has a 50 day simple moving average of $9.35 and a 200 day simple moving average of $14.11. The firm has a market cap of $578.93 million, a price-to-earnings ratio of -29.47 and a beta of 1.61.

Codexis (NASDAQ:CDXS - Get Rating) last issued its earnings results on Thursday, August 4th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.08. Codexis had a negative return on equity of 11.63% and a negative net margin of 14.03%. The business had revenue of $38.41 million for the quarter, compared to analyst estimates of $37.86 million. During the same period last year, the company posted ($0.07) EPS. The business's quarterly revenue was up 50.9% on a year-over-year basis. On average, analysts predict that Codexis will post -0.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Cowen cut their price target on Codexis from $39.00 to $21.00 in a report on Friday, July 15th. HC Wainwright decreased their price target on shares of Codexis from $27.00 to $25.00 and set a "buy" rating on the stock in a research note on Monday, August 8th. Cowen cut their price objective on shares of Codexis from $39.00 to $21.00 and set an "outperform" rating for the company in a research report on Friday, July 15th. Piper Sandler lowered their target price on shares of Codexis from $35.00 to $22.00 and set an "overweight" rating for the company in a research note on Thursday, July 14th. Finally, Benchmark set a $20.00 price target on Codexis in a research note on Tuesday, July 19th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, Codexis has a consensus rating of "Moderate Buy" and an average price target of $21.33.

Receive CDXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter.

CDXS Stock News Headlines

Codexis (NASDAQ:CDXS) PT Lowered to $25.00
Codexis (NASDAQ:CDXS) Trading Down 6.2% on Analyst Downgrade
Codexis (NASDAQ:CDXS) Shares Up 9.3% Following Strong Earnings
Codexis: Q2 Earnings Snapshot
Codexis (CDXS) Set to Announce Quarterly Earnings on Thursday
Codexis (NASDAQ:CDXS) Stock Price Down 4.8%
Codexis (NASDAQ:CDXS) Shares Gap Up to $7.84
Codexis (NASDAQ:CDXS) Trading Up 9%
Codexis Shares Slide On CEO Transition
See More Headlines
Receive CDXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter.

CDXS Company Calendar

Last Earnings
8/04/2022
Today
8/13/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Industrial organic chemicals
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CDXS
CUSIP
19200510
Employees
261
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.33
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$19.00
Forecasted Upside/Downside
+141.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-21,280,000.00
Pretax Margin
-13.81%

Debt

Sales & Book Value

Annual Sales
$104.75 million
Book Value
$2.43 per share

Miscellaneous

Free Float
60,909,000
Market Cap
$578.93 million
Optionable
Optionable
Beta
1.61

Key Executives

  • Mr. John J. Nicols (Age 58)
    Pres, CEO & Director
    Comp: $1.33M
  • Mr. Ross Taylor Jr. (Age 59)
    M.B.A., Sr. VP & CFO
    Comp: $667.31k
  • Dr. Karl A. Schoene Ph.D.
    Sr. VP of Devel. & Operations
  • Ms. Asli Aras Ph.D.
    VP of Corp. Devel.
  • Ms. Karen Frechou-Armijo
    Sr. VP & Head of HR
  • Dr. Gjalt Huisman Ph.D.
    Sr. VP of Strategic Devel. & GM of Biotherapeutics
  • Mr. Rob Wilson Ph.D.
    Sr. VP & GM of Performance Enzymes
  • Dr. Stefan Lutz Ph.D.
    Sr. VP of Research
  • Mr. Robert Sato M.B.A.
    Ph.D., Sr. VP of Pharmaceutical Devel., Quality & Regulatory
  • Prof. Gerhard N. Mayr (Age 76)
    Special Advisor to the Board













CDXS Stock - Frequently Asked Questions

Should I buy or sell Codexis stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CDXS shares.
View CDXS analyst ratings
or view top-rated stocks.

What is Codexis' stock price forecast for 2022?

5 Wall Street research analysts have issued 12 month price objectives for Codexis' stock. Their CDXS share price forecasts range from $19.00 to $25.00. On average, they expect the company's stock price to reach $21.33 in the next twelve months. This suggests a possible upside of 141.3% from the stock's current price.
View analysts price targets for CDXS
or view top-rated stocks among Wall Street analysts.

How have CDXS shares performed in 2022?

Codexis' stock was trading at $31.27 at the beginning of the year. Since then, CDXS shares have decreased by 71.7% and is now trading at $8.84.
View the best growth stocks for 2022 here
.

When is Codexis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our CDXS earnings forecast
.

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) issued its quarterly earnings results on Thursday, August, 4th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.08. The biotechnology company had revenue of $38.41 million for the quarter, compared to analyst estimates of $37.86 million. Codexis had a negative net margin of 14.03% and a negative trailing twelve-month return on equity of 11.63%. The firm's quarterly revenue was up 50.9% on a year-over-year basis. During the same period last year, the business earned ($0.07) earnings per share.

What guidance has Codexis issued on next quarter's earnings?

Codexis issued an update on its FY 2022 earnings guidance on Thursday, August, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $135.00 million-$141.00 million, compared to the consensus revenue estimate of $137.67 million.

What is John J. Nicols' approval rating as Codexis' CEO?

25 employees have rated Codexis Chief Executive Officer John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Codexis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).

What is Codexis' stock symbol?

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Who are Codexis' major shareholders?

Codexis' stock is owned by a variety of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (11.33%), ARK Investment Management LLC (6.87%), Allspring Global Investments Holdings LLC (4.62%), FMR LLC (2.73%), Assenagon Asset Management S.A. (2.28%) and Sumitomo Mitsui Trust Holdings Inc. (1.70%). Insiders that own company stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, John J Nicols, Patrick Y Yang and Thomas R Baruch.
View institutional ownership trends
.

How do I buy shares of Codexis?

Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Codexis' stock price today?

One share of CDXS stock can currently be purchased for approximately $8.84.

How much money does Codexis make?

Codexis (NASDAQ:CDXS) has a market capitalization of $578.93 million and generates $104.75 million in revenue each year. The biotechnology company earns $-21,280,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis.

How many employees does Codexis have?

The company employs 261 workers across the globe.

How can I contact Codexis?

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.codexis.com. The biotechnology company can be reached via phone at (650) 421-8100, via email at ir@codexis.com, or via fax at 650-421-8102.

This page (NASDAQ:CDXS) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.